David Devos
YOU?
Author Swipe
View article: <scp>AZP2006</scp> in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open‐Label Extension on Safety, Biomarkers, and Disease Progression
<span>AZP2006</span> in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open‐Label Extension on Safety, Biomarkers, and Disease Progression Open
Objectives The aim was to evaluate the safety, tolerability, pharmacokinetics, and potential clinical efficacy of AZP2006, an oral pleiotropic drug modulating progranulin levels, in patients with progressive supranuclear palsy (PSP), a rar…
View article: Parkinson’s disease and multiple system atrophy are gateways to <i>RFC1</i>-related disorders
Parkinson’s disease and multiple system atrophy are gateways to <i>RFC1</i>-related disorders Open
Biallelic pathogenic expansions of the RFC1 gene are the genetic cause of cerebellar ataxia, neuropathy, and bilateral vestibular areflexia syndrome. Sensory neuropathy is the most common symptom, but the clinical impairments and gateways …
View article: The Two Faces of Pediatric <scp>SCA2</scp>
The Two Faces of Pediatric <span>SCA2</span> Open
Introduction Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurological disease usually described in adults. Expanded CAG repeats in the ATXN2 gene can lead to pediatric onset. This study aims to describe the natural histor…
View article: Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease
Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease Open
Background Parkinson's disease (PD) patients on dopaminergic drugs may experience non-motor fluctuations (NMFs) which are often heterogeneous and respond variably to treatments. Objective We evaluated if personality was associated to NMFs …
View article: Texture features of T2w magnetic resonance imaging mirror tissue changes in Parkinson’s disease models
Texture features of T2w magnetic resonance imaging mirror tissue changes in Parkinson’s disease models Open
After successful applications in the oncology field to provide new in vivo diagnosis and prognosis imaging features, texture analysis and more generally radiomics were also reported as having the potential to provide markers of different n…
View article: Parkinson's Disease, Speech and Neurosurgery
Parkinson's Disease, Speech and Neurosurgery Open
Background Speech impairment is a recognized but unpredictable adverse effect of sub‐thalamic nucleus deep brain stimulation (STN‐DBS) for Parkinson's disease (PD). Objectives To evaluate the prevalence of speech impairment 1 year after ST…
View article: Conservative iron chelation for VAC14: Two-year clinical-radiological follow-up
Conservative iron chelation for VAC14: Two-year clinical-radiological follow-up Open
There is a distinct lack of consensus on the most effective treatments for neurodegeneration with brain iron accumulation. This is due to the rarity of the disease, its phenotypic variability, and the multiplicity of pathophysiological mec…
View article: LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode
LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode Open
Acyl‐coenzyme A synthetase long‐chain family member 4 (ACSL4), a pivotal enzyme in lipid metabolism, has emerged as a therapeutic target for ferroptosis‐related conditions and cancer. However, its reference inhibitor, rosiglitazone, has of…
View article: LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode
LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode Open
Acyl‐coenzyme A synthetase long‐chain family member 4 (ACSL4), a pivotal enzyme in lipid metabolism, has emerged as a therapeutic target for ferroptosis‐related conditions and cancer. However, its reference inhibitor, rosiglitazone, has of…
View article: Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies
Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies Open
Background Reducing nigrostriatal iron overload reduces neuronal loss in Parkinson's disease (PD) models. Objective Examine the safety and efficacy of deferiprone in reducing motor disability progression in dopaminergic-treated and treatme…
View article: Metabolic connectivity of freezing in Parkinson's disease
Metabolic connectivity of freezing in Parkinson's disease Open
Background Freezing of gait (FoG) is among the most disabling gait disorders of Parkinson's disease. The full understanding of its mechanisms requires a network study approach. So far, FoG was mainly studied using magnetic resonance imagin…
View article: Expression of concern: Sensing of COVID-19 spike protein in nasopharyngeal samples using a portable surface plasmon resonance diagnostic system
Expression of concern: Sensing of COVID-19 spike protein in nasopharyngeal samples using a portable surface plasmon resonance diagnostic system Open
Expression of concern for ‘Sensing of COVID-19 spike protein in nasopharyngeal samples using a portable surface plasmon resonance diagnostic system’ by Hiba Saada et al. , Sens. Diagn. , 2022, 1 , 1021–1031, https://doi.org/10.1039/D2SD000…
View article: Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials
Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials Open
Background Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease with diverse clinical phenotypes, prompting the development of new diagnostic criteria known as the MDS-PSP classification. However, little is known about …
View article: Neuroprotective effects of intranasal extracellular vesicles from human platelet concentrates supernatants in traumatic brain injury and Parkinson’s disease models
Neuroprotective effects of intranasal extracellular vesicles from human platelet concentrates supernatants in traumatic brain injury and Parkinson’s disease models Open
Background The burgeoning field of regenerative medicine has significantly advanced with recent findings on biotherapies using human platelet lysates (HPLs), derived from clinical-grade platelet concentrates (PCs), for treating brain disor…
View article: Dysregulation of muscle cholesterol transport in amyotrophic lateral sclerosis
Dysregulation of muscle cholesterol transport in amyotrophic lateral sclerosis Open
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting motor neurons, with a typical lifespan of 3–5 years. Altered metabolism is a key feature of ALS that strongly influences prognosis, with an increase …
View article: Caffeine consumption outcomes on amyotrophic lateral sclerosis disease progression and cognition
Caffeine consumption outcomes on amyotrophic lateral sclerosis disease progression and cognition Open
Caffeine consumption outcomes on Amyotrophic Lateral Sclerosis (ALS) including progression, survival and cognition remain poorly defined and may depend on its metabolization influenced by genetic variants. 378 ALS patients with a precise e…
View article: Pharmacological neuromodulation by intracerebroventricular administration of anaerobic dopamine in the treatment of advanced Parkinson's disease
Pharmacological neuromodulation by intracerebroventricular administration of anaerobic dopamine in the treatment of advanced Parkinson's disease Open
Continuous compensation of cerebral dopamine deficiency represents an ideal treatment for Parkinson's disease. However, dopamine does not cross the digestive and blood-brain barriers, and is rapidly oxidised. The new concept is continuous …
View article: Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: <scp>OXYDOPA</scp> Trial
Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: <span>OXYDOPA</span> Trial Open
Background Among the different types of pain related to Parkinson's disease (PD), parkinsonian central pain (PCP) is the most disabling. Objectives We investigated the analgesic efficacy of two therapeutic strategies (opioid with oxycodone…
View article: Effectiveness of Continuous Dopaminergic Therapies in Parkinson’s Disease: A Review of L-DOPA Pharmacokinetics/Pharmacodynamics
Effectiveness of Continuous Dopaminergic Therapies in Parkinson’s Disease: A Review of L-DOPA Pharmacokinetics/Pharmacodynamics Open
Background: Parkinson’s disease (PD) is characterized by striatal dopamine deficiency. Since dopamine cannot cross the digestive and blood-brain barriers, its precursor, levodopa (L-DOPA), remains the mainstay of treatment. However, the si…
View article: SurLym trial: study protocol for a multicentre pragmatic randomised controlled trial on the added value of reconstructive lymphatic surgery to decongestive lymphatic therapy for the treatment of lymphoedema
SurLym trial: study protocol for a multicentre pragmatic randomised controlled trial on the added value of reconstructive lymphatic surgery to decongestive lymphatic therapy for the treatment of lymphoedema Open
Introduction Lymphoedema is a chronic condition caused by lymphatic insufficiency. It leads to swelling of the limb/midline region and an increased risk of infection. Lymphoedema is often associated with mental and physical problems limiti…
View article: Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative Open
In 2011, the UK medical research charity Cure Parkinson’s set up the international Linked Clinical Trials (iLCT) committee to help expedite the clinical testing of potentially disease modifying therapies for Parkinson’s disease (PD). The f…
View article: Long-term inhibition of lysosomal glucocerebrosidase activity promotes GPX4 stability and inhibits ferroptosis in a Parkinson’s model
Long-term inhibition of lysosomal glucocerebrosidase activity promotes GPX4 stability and inhibits ferroptosis in a Parkinson’s model Open
An increasing number of studies indicate that ferroptosis, a lethal pathway initiated by excessive iron-dependent lipid peroxidation, and pivotal to the survival of dopaminergic neurons and the progression of Parkinson’s disease (PD), may …